Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

Promising outcomes for world's first leadless LBBAP procedures | Elevated risks for some heart pump patients | Stents & CTO PCI

News You Need to Know Today
Promising outcomes for world's first leadless LBBAP procedures | Elevated risks for some heart pump patients | Stents & CTO PCI
Wednesday, May 7, 2025
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Today's News and Trends

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 

READ MORE >
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Share on Twitter Share on Facebook Share on Linkedin

World’s first leadless LBBAP procedures linked to ‘promising’ outcomes

Share on Twitter Share on Facebook Share on Linkedin
2024 has been a banner year for structural heart treatments, especially those focused on the tricuspid valve. In February, for example, Edwards Lifesciences made history when its Evoque transcatheter tricuspid valve replacement (TTVR) system became the first device of its kind to gain U.S. Food and Drug Administration (FDA) approval for treating tricuspid regurgitation (TR). Two months later, Abbott’s TriClip transcatheter edge-to-edge repair (TEER) system also gained FDA approval for the treatment of TR.
Cardiologists are turning to leadless pacemakers more and more for cardiac pacing, but those devices have not previously been able to perform LBBAP. This new analysis includes new data on the world’s very first leadless LBBAP procedures. 
READ MORE >

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure. 

READ MORE >
Abbott’s HeartMate 3 left ventricular assist device (LVAD) has been implanted in thousands of U.S. patients in recent years.According to a new investigative report from CBS News and KFF Health News, however, safety data related to the device have raised questions in certain parts of the healthcare industry.
Share on Twitter Share on Facebook Share on Linkedin

Smaller LV dimensions may increase risk of death for HeartMate 3 LVAD patients

Share on Twitter Share on Facebook Share on Linkedin
Abbott’s HeartMate 3 left ventricular assist device (LVAD) has been implanted in thousands of U.S. patients in recent years.According to a new investigative report from CBS News and KFF Health News, however, safety data related to the device have raised questions in certain parts of the healthcare industry.
Researchers tracked short- and long-term data from nearly 2,000 patients, presenting their findings in JACC: Heart Failure. 
READ MORE >

Stenting ‘an important treatment option’ for PCI patients with complete blockages

The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."

READ MORE >
heart-stent.jpg
Share on Twitter Share on Facebook Share on Linkedin

Stenting ‘an important treatment option’ for PCI patients with complete blockages

Share on Twitter Share on Facebook Share on Linkedin
heart-stent.jpg
The study's lead author emphasized that stenting during CTO PCI procedures "should be considered safe and effective in the long term."
READ MORE >

Featured Articles

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.

READ MORE >
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Share on Twitter Share on Facebook Share on Linkedin

Tirzepatide bests semaglutide in patients with type 2 diabetes, kidney disease and heart failure

Share on Twitter Share on Facebook Share on Linkedin
tirzepatide injections Zepbound Eli Lilly. The U.S. Food and Drug Administration (FDA) cleared Eli Lilly and Company’s tirzepatide injections for chronic weight management in adult patients who are obese, overweight or present with at least one weight-related condition such as high blood pressure or high cholesterol. These weekly injections are being sold and distributed under the brand name Zepbound. Tirzepatide is also used in Mounjaro, FDA cleared in 2022 for improving glycemic control in adults.
Researchers examined data from more than 9,000 patients, sharing their findings at SCAI 2025.
READ MORE >

AI predicts LBBB risk in TAVR patients prior to treatment

The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.

READ MORE >
artificial intelligence heart AI
Share on Twitter Share on Facebook Share on Linkedin

AI predicts LBBB risk in TAVR patients prior to treatment

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence heart AI
The authors tested out a variety of machine learning techniques, including large language models and more traditional algorithms. They focused on data that can be gathered prior to treatment, ensuring cardiologists know as much as possible before the procedure.
READ MORE >

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.

READ MORE >
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Share on Twitter Share on Facebook Share on Linkedin

New SCAI president lists advocacy, cardiogenic shock among his top priorities

Share on Twitter Share on Facebook Share on Linkedin
Srihari S. Naidu, MD, FACC, FAHA, MSCAI, assumed the role of president of the Society for Cardiovascular Angiography and Interventions (SCAI) May 3 during the society's annual meeting. He outlined his ambitious plans to take SCAI in some new directions. #SCAI #SCAI2025
Srihari Naidu, MD, spoke to Cardiovascular Business about his plan to take SCAI in some bold new directions.
READ MORE >

In Case You Missed It

FDA sees potential in new pacemaker-guided hypertension therapy

Orchestra BioMed and Medtronic have worked together on the new therapy, which is designed to work automatically without patients needing to take any additional steps.

READ MORE >
Orchestra BioMed Holdings AVIM Therapy FDA breakthrough device
Share on Twitter Share on Facebook Share on Linkedin

FDA sees potential in new pacemaker-guided hypertension therapy

Share on Twitter Share on Facebook Share on Linkedin
Orchestra BioMed Holdings AVIM Therapy FDA breakthrough device
Orchestra BioMed and Medtronic have worked together on the new therapy, which is designed to work automatically without patients needing to take any additional steps.
READ MORE >

SCAI pushes for better radiation protection in cath labs

Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.

READ MORE >
Society of Cardiovascular Angiography and Interventions (SCAI) President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center in Indianapolis, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons that cause orthopedic injury.
Share on Twitter Share on Facebook Share on Linkedin

SCAI pushes for better radiation protection in cath labs

Share on Twitter Share on Facebook Share on Linkedin
Society of Cardiovascular Angiography and Interventions (SCAI) President James B. Hermiller, Jr., MD, director of the transcatheter structural heart program at Ascension St. Vincent Heart Center in Indianapolis, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons that cause orthopedic injury.
Society of Cardiovascular Angiography and Interventions President James Hermiller, Jr., MD, explains SCAI's push for wider adoption of new, innovative cath lab radiation protection technology to reduce radiation exposure and the need for lead aprons.
READ MORE >

Perfuze celebrates a ‘major milestone’ for new-look stroke catheter

The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels. 

READ MORE >
Perfuze Millipede 088 catheter
Share on Twitter Share on Facebook Share on Linkedin

Perfuze celebrates a ‘major milestone’ for new-look stroke catheter

Share on Twitter Share on Facebook Share on Linkedin
Perfuze Millipede 088 catheter
The Millipede 088 was designed to treat large vessel occlusion stroke patients by “ingesting” the blood clot as opposed to dragging it through the patient’s blood vessels. 
READ MORE >

In Other News

Healthcare AI newswatch: UnitedHealth hearts AI, agentic AI again, healthcare AI dependency, more

Give healthcare workers AI to do their jobs and you might make them AI-dependent. Give them AI anyway?

READ MORE >
artificial intelligence AI in healthcare
Share on Twitter Share on Facebook Share on Linkedin

Healthcare AI newswatch: UnitedHealth hearts AI, agentic AI again, healthcare AI dependency, more

Share on Twitter Share on Facebook Share on Linkedin
artificial intelligence AI in healthcare
Give healthcare workers AI to do their jobs and you might make them AI-dependent. Give them AI anyway?
READ MORE >

First, do no AI: How not to help the world’s struggling healthcare systems

An international team of researchers is calling on healthcare AI proponents to be more mindful of the technology’s unsuitability across much of the developing world. 

READ MORE >
Artificial Intelligence AI in healthcare
Share on Twitter Share on Facebook Share on Linkedin

First, do no AI: How not to help the world’s struggling healthcare systems

Share on Twitter Share on Facebook Share on Linkedin
Artificial Intelligence AI in healthcare
An international team of researchers is calling on healthcare AI proponents to be more mindful of the technology’s unsuitability across much of the developing world. 
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

News Alert: CMS proposes major TAVR changes
Cath lab kits recalled | Looking ahead to the future of FFR-CT | Medtronic completes major acquisition
FDA sees potential in heart failure software | SCCT & SCAI take on CT-derived FFR | Predicting long-term stroke risk
Abbott recalls heart monitoring tech | Redo TAVR with balloon-expandable valves | FDA clears new clot-removing device
Week in Review: Star Trek star's family awarded $13M | AI for cardiac amyloidosis | TAVR concerns | New CKM syndrome guidelines
A brand new payment model | Cardiologist compensation keeps rising | Major medtech player invests $1.5B in TAVR tech
Death after TAVR: New data support a change | Rural hospital in spotlight for wrong reason | Heart changes linked to cancer risk

Pagination

    • Current page 1
    • Page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9 …
    • Next page ››
    • Last page Last »
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
 
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
 
Design by Adaptive Theme
Trimed Popup